Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients.

Xu SS, Alexander PK, Lie Y, Dore V, Bozinovski S, Mulligan RS, Young K, Villemagne VL, Rowe CC.

BMJ Open. 2018 Nov 15;8(11):e025533. doi: 10.1136/bmjopen-2018-025533.

2.

18F-Florbetaben PET beta-amyloid binding expressed in Centiloids.

Rowe CC, Doré V, Jones G, Baxendale D, Mulligan RS, Bullich S, Stephens AW, De Santi S, Masters CL, Dinkelborg L, Villemagne VL.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2053-2059. doi: 10.1007/s00259-017-3749-6. Epub 2017 Jun 22.

3.

Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with 18F-AV133 and PET.

Alexander PK, Lie Y, Jones G, Sivaratnam C, Bozinvski S, Mulligan RS, Young K, Villemagne VL, Rowe CC.

J Nucl Med. 2017 Nov;58(11):1815-1820. doi: 10.2967/jnumed.116.189019. Epub 2017 May 10.

4.

Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale.

Rowe CC, Jones G, Doré V, Pejoska S, Margison L, Mulligan RS, Chan JG, Young K, Villemagne VL.

J Nucl Med. 2016 Aug;57(8):1233-7. doi: 10.2967/jnumed.115.171595. Epub 2016 Feb 16.

5.

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL.

Brain. 2014 Jun;137(Pt 6):1762-71. doi: 10.1093/brain/awu064. Epub 2014 Mar 27.

PMID:
24681664
6.

Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.

Fodero-Tavoletti MT, Furumoto S, Taylor L, McLean CA, Mulligan RS, Birchall I, Harada R, Masters CL, Yanai K, Kudo Y, Rowe CC, Okamura N, Villemagne VL.

Alzheimers Res Ther. 2014 Feb 26;6(1):11. doi: 10.1186/alzrt240. eCollection 2014.

7.

In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.

Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):816-26. doi: 10.1007/s00259-013-2681-7. Epub 2014 Feb 11.

PMID:
24514874
8.

Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.

Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y.

J Nucl Med. 2013 Aug;54(8):1420-7. doi: 10.2967/jnumed.112.117341. Epub 2013 Jul 15.

9.

Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.

Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, Cselényi Z, Masters CL, Villemagne VL.

J Nucl Med. 2013 Jun;54(6):880-6. doi: 10.2967/jnumed.112.114785. Epub 2013 Apr 10.

10.

(18)F-florbetaben Aβ imaging in mild cognitive impairment.

Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chételat G, Raniga P, Mulligan RS, Salvado O, Putz B, Roth K, Masters CL, Reininger CB, Rowe CC.

Alzheimers Res Ther. 2013 Jan 16;5(1):4. doi: 10.1186/alzrt158. eCollection 2013.

11.

Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease.

Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC.

Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):983-9. doi: 10.1007/s00259-012-2088-x. Epub 2012 Mar 8.

PMID:
22398958
12.

Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.

Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, O'Keefe G, Jones G, Kung HF, Pontecorvo M, Masters CL, Skovronsky DM, Rowe CC.

Neurodegener Dis. 2012;10(1-4):161-5. doi: 10.1159/000334535. Epub 2012 Jan 17.

PMID:
22261520
13.

Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.

Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC.

J Nucl Med. 2011 Aug;52(8):1210-7. doi: 10.2967/jnumed.111.089730. Epub 2011 Jul 15.

14.

In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.

Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, Ackermann U, O'Keefe G, Jones G, Gong S, Tochon-Danguy H, Kung HF, Masters CL, Skovronsky DM, Rowe CC.

Arch Neurol. 2011 Jul;68(7):905-12. doi: 10.1001/archneurol.2011.142.

PMID:
21747030
15.

18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.

Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL.

Brain. 2011 Apr;134(Pt 4):1089-100. doi: 10.1093/brain/awr038. Epub 2011 Mar 24.

PMID:
21436112
16.

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC.

Ann Neurol. 2011 Jan;69(1):181-92. doi: 10.1002/ana.22248.

17.

Temperature elevation increases GABA(A) -mediated cortical inhibition in a mouse model of genetic epilepsy.

Hill EL, Hosie S, Mulligan RS, Richards KL, Davies PJ, Dubé CM, Baram TZ, Reid CA, Jones MV, Petrou S.

Epilepsia. 2011 Jan;52(1):179-84. doi: 10.1111/j.1528-1167.2010.02914.x. Epub 2010 Dec 22.

18.

Quantitative approaches to amyloid imaging.

Villemagne VL, O'Keefe G, Mulligan RS, Rowe CC.

Methods Mol Biol. 2011;680:201-25. doi: 10.1007/978-1-60761-901-7_14.

PMID:
21153383
19.

In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.

Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O'Keefe G, Jones G, Kung HF, Pontecorvo MJ, Skovronsky D, Rowe CC.

J Nucl Med. 2010 Feb;51(2):223-8. doi: 10.2967/jnumed.109.070094. Epub 2010 Jan 15.

20.

In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.

Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL.

Eur J Pharmacol. 2009 Sep 1;617(1-3):54-8. doi: 10.1016/j.ejphar.2009.06.042. Epub 2009 Jul 1.

PMID:
19576880
21.

The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380.

Ellis JR, Nathan PJ, Villemagne VL, Mulligan RS, Ellis KA, Tochon-Danguy HJ, Chan JG, O'keefe GJ, Bradley J, Savage G, Rowe CC.

Synapse. 2009 Sep;63(9):752-63. doi: 10.1002/syn.20642.

PMID:
19484724
22.

Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.

Ellis JR, Nathan PJ, Villemagne VL, Mulligan RS, Saunder T, Young K, Smith CL, Welch J, Woodward M, Wesnes KA, Savage G, Rowe CC.

Psychopharmacology (Berl). 2009 Jan;202(1-3):79-91. doi: 10.1007/s00213-008-1347-9. Epub 2008 Oct 24.

PMID:
18949462
23.

Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.

Ellis JR, Villemagne VL, Nathan PJ, Mulligan RS, Gong SJ, Chan JG, Sachinidis J, O'Keefe GJ, Pathmaraj K, Wesnes KA, Savage G, Rowe CC.

Neurobiol Learn Mem. 2008 Sep;90(2):404-12. doi: 10.1016/j.nlm.2008.05.006. Epub 2008 Jul 11.

PMID:
18620875
24.

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients.

Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, Ell PJ.

Mol Psychiatry. 2006 Feb;11(2):118-9. No abstract available.

PMID:
16189506
25.

Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET.

Mitkovski S, Villemagne VL, Novakovic KE, O'Keefe G, Tochon-Danguy H, Mulligan RS, Dickinson KL, Saunder T, Gregoire MC, Bottlaender M, Dolle F, Rowe CC.

Nucl Med Biol. 2005 Aug;32(6):585-91.

PMID:
16026705
26.

Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo.

Bressan RA, Erlandsson K, Stone JM, Mulligan RS, Krystal JH, Ell PJ, Pilowsky LS.

Biol Psychiatry. 2005 Jul 1;58(1):41-6.

PMID:
15992521
27.

A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261.

Bressan RA, Erlandsson K, Mulligan RS, Gunn RN, Cunningham VJ, Owens J, Cullum ID, Ell PJ, Pilowsky LS.

Nucl Med Biol. 2004 Feb;31(2):155-64.

PMID:
15013480
28.

Evaluation of NMDA receptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findings.

Bressan RA, Erlandsson K, Mulligan RS, Gunn RN, Cunningham VJ, Owens J, Ell PJ, Pilowsky LS.

Ann N Y Acad Sci. 2003 Nov;1003:364-7. No abstract available.

PMID:
14684462
29.

Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT4 receptors with SPET.

Pike VW, Halldin C, Nobuhara K, Hiltunen J, Mulligan RS, Swahn CG, Karlsson P, Olsson H, Hume SP, Hirani E, Whalley J, Pilowsky LS, Larsson S, Schnell PO, Ell PJ, Farde L.

Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1520-8. Epub 2003 Sep 23.

PMID:
14579092
30.

Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings.

Erlandsson K, Bressan RA, Mulligan RS, Ell PJ, Cunningham VJ, Pilowsky LS.

Neuroimage. 2003 Jul;19(3):1205-14.

PMID:
12880845
31.

Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor.

Erlandsson K, Bressan RA, Mulligan RS, Gunn RN, Cunningham VJ, Owens J, Wyper D, Ell PJ, Pilowsky LS.

Nucl Med Biol. 2003 May;30(4):441-54.

PMID:
12767402
32.

Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.

Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS.

J Clin Psychopharmacol. 2003 Feb;23(1):5-14.

PMID:
12544369
33.

Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.

Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Kerwin RW, Pilowsky LS.

Br J Psychiatry. 2000 Nov;177:408-15.

PMID:
11059993
34.

Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.

Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS.

Psychopharmacology (Berl). 2000 Jun;150(2):132-40.

PMID:
10907666
35.

In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study.

Bigliani V, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Stephenson C, Kerwin RW, Pilowsky LS.

Br J Psychiatry. 1999 Sep;175:231-8.

PMID:
10645324
36.

Limbic selectivity of clozapine.

Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW.

Lancet. 1997 Aug 16;350(9076):490-1. No abstract available.

PMID:
9274589
37.
38.

The integrative control of adrenocorticotrophin secretion: a critical role for corticotrophin-releasing hormone.

Evans MJ, Mulligan RS, Livesey JH, Donald RA.

J Endocrinol. 1996 Mar;148(3):475-83.

PMID:
8778226
39.

Supplemental Content

Loading ...
Support Center